Polymorphous low-grade adenocarcinoma (PLGA) shows histologic diversity with fascicular and targetoid features while cribriform adenocarcinoma of salivary gland (CASG) demonstrates predominant cribriform and solid patterns with glomeruloid appearance and optical clear nuclei. The current study is designed to identify pathologic features that may predict clinical outcome in 69 PLGA/CASG. Seven patients had recurrences or distant metastasis, including 3 local recurrences, 2 nodal metastases, and 2 distant metastases. The following histologic factors predicted disease-free survival on univariate analysis: tumor size, bone invasion, lymphovascular invasion, tumor necrosis, Z10% papillary pattern, and Z30% cribriform pattern. On multivariate analysis, 10% of papillary pattern and 30% cribriform pattern were independent prognostic factors of disease-free survival. Histologic classification of the 69 tumors (based on the prior reported definition of CASG) showed 21 CASGs (30%), 23 PLGAs (33%), and 22 (32%) with indeterminate features of PLGA and CASG. In addition, 3 (4%) tumors demonstrated a predominant papillary pattern (Z50%). Interestingly, not all CASGs were located in the minor salivary gland and 2 tumors were identified in the parotid. One patient died from her disease and she harbored a CASG with >30% cribriform pattern. In conclusion, tumor size, bone invasion, and lymphovascular invasion are significant parameters that can predict adverse clinical behaviors in PLGA/CASG on univariate analysis. Using the prior reported definition, an overlapping histology between PLGA and CASG was noted in over a third of the cases. Regardless of tumor subclassification, the per-centage of cribriform and papillary patterns seems to be prognostically relevant and should be documented.
P olymorphous low-grade adenocarcinoma (PLGA) was first proposed by Evans and Batsakis 1 in 1984 as a distinct tumor type of the salivary gland characterized by cytologic uniformity and architectural diversity. Since then, PLGA has been accepted as a major type of malignant salivary gland epithelial tumor and was adopted in the World Health Organization (WHO) classification. 2 A majority of PLGAs originates from the minor salivary glands, in particular the palate. Currently, PLGA constitutes the second most common malignant oral minor salivary gland tumor, accounting for 11% of all oral salivary gland tumors and 26% of all malignant ones. 3 In general, PLGA is considered as a low-grade salivary gland malignancy with an overall recurrence rate of 19.1%, 4 a risk of regional lymph node metastasis of 13% to 17%, 5, 6 and a 0.6% to 7.5% risk of distant metastasis. 5, 7 To date, little is known about the histopathologic features that influence outcome in PLGA. Univariate survival analysis has been performed only in 2 published studies of 40 and 24 patients, and failed to establish any significant pathologic factors that might predict survival. 5, 6 Hence, a larger scale study with long-term follow-up data and appropriate statistical analysis is necessary to identify helpful prognostic pathologic features in this disease.
Moreover, there have been controversies in the literature regarding the diagnosis of low-grade papillary adenocarcinoma ( LGPA, or PLGA with papillary pattern) and cribriform adenocarcinoma of salivary gland (CASG) and whether these 2 tumors represent separate entities or variants of PLGA. 5, [8] [9] [10] [11] Although LGPA has been used to describe tumors with "more than focal" papillary growth pattern, 5, 8, 12 the term cribriform adenocarcinoma has been proposed for carcinoma with a predominant cribriform and solid architecture with glomeruloid appearance and optical clear nuclei. 9, 10 A few studies have shown that CASGs and LGPAs are associated with higher risk of regional and distant metastases, compared with the classical PLGAs. 5, [8] [9] [10] 12 Therefore, several groups have proposed to classify LGPA and CASG as entities distinct from PLGA to emphasize their aggressive behaviors. [8] [9] [10] 13 These tumors were included as variants of PLGA in the WHO classification of 2005 2 but the controversies remain unresolved and uniform diagnostic criteria are yet to be formed. As these subtypes appear to have different outcomes and might be difficult to classify histologically, there is a need to identify prognostic histologic factors within the entire spectrum of PLGA/CASG. Toward that goal, we performed a meticulous histopathologic and clinical analysis of a large retrospective cohort of patients treated and followed at a single institution.
MATERIALS AND METHODS

Inclusion Criteria, Histologic Definitions, and Classification
After obtaining Institutional Review Board approval, the pathology database was searched for cases of PLGA, papillary adenocarcinoma, or cribriform adenocarcinoma diagnosed at Memorial Sloan-Kettering Cancer Center (MSKCC, New York, NY) between 1987 and 2015. A total of 93 surgical specimens from 69 patients with adequate materials (ie, resections or large incisional biopsies) were included in the present study. A median of 6 tumor sections (range, 1 to 17) were studied per primary tumor. These tumors were subsequently subjected to detailed histopathologic analyses by 2 pathologists with special interest in salivary gland neoplasia (N.K., B.X.) and were further classified as one of the following categories: (1) PLGA; (2) CASG; (3) tumors with indeterminate features (TIFs); and (4) tumors with a predominant papillary pattern (TPPP). PLGA and CASG were defined as described in the WHO of 2005 2 and in the prior publications of Skalova and colleagues. 9, 10, 14 In Brief, PLGA was characterized as an infiltrative carcinoma with architectural diversity, in particular short fascicles and single files in a targetoid arrangement. 2 CASG displayed architectural uniformity with a predominant cribriform and solid growth patterns, sometimes demonstrating peripheral palisading, peripheral clefting, and glomeruloid appearance. 9 TIFs displayed significant areas typical of PLGA and CASG. Lastly, tumors containing a large component (Z50%) of papillary architecture were classified as tumors with predominant papillary pattern ( Fig. 1 ). All studied tumors exhibited cytologic uniformity with pale vesicular nuclei resembling those of papillary thyroid carcinoma. Subsequently, discrepant cases were rereviewed to reach a consensus diagnosis. Interobserver agreement analysis was performed between 3 head and neck pathologists (R.G., N.K., B.X.), as well as between each individual pathologist and the consensus diagnosis.
Pathology and Immunohistochemical Review
The following histomorphologic features of the primary tumors were reviewed and documented: tumor size, mitotic index, atypical mitosis, percentage of optical clear nuclei, tumor necrosis, apoptotic bodies, invasive tumor front (infiltrative vs. pushing border), involved structures (lamina propria, skeletal muscle, or bone), margin status, percentage of different architectural patterns, lymphovascular invasion (LVI), and perineural invasion (PNI). Lastly, if a neck dissection was performed at the time of surgery, lymph node metastasis, including the number and size of involved nodes was recorded. Mitotic index was determined by counting 10 high-power fields (HPFs, Â 400, total field size 2.4 mm 2 ) with an Olympus microscope (U-DO model BX41; Olympus America Inc., Center Valley, PA) in the areas of highest concentration of mitotic figures. Microscopic margins were categorized as positive (tumor at the inked margin), close (tumor within 1 mm from the inked margin), or negative (tumor >1 mm from the inked margin). The architectural patterns of the primary tumor were defined as follows ( Fig. 2 ): (1) single filing: in which the tumor cells were arranged as single columns, often surrounding nerves and blood vessels in a targetoid appearance; (2) tubular: in which tumor cells formed round or elongated tubules with definite lumen formation; (3) trabecular: in which tumor cells were arranged as a mixture of thin and thick elongated trabeculae; (4) anastomosing reticulartrabecular (reticular): in which the tumor exhibited thin and thick anastomosing cords often in a background of myxoid stroma; (5) solid: in which tumor cells formed large solid sheets; (6) papillary: in which papillae with or without central fibrovascular cores were present; and (7) cribriform: in which back to back cylindrical structures contained eosinophilic extracellular matrix and resembled the cribriform pattern of adenoid cystic carcinoma.
Immunohistochemical stains for p63, p40, MIB-1, and S100 were performed using the Ventana system according to the manufacturer recommendations (Ventana Medical Systems Inc., Tucson, AZ). Forty-six cases were stained for p40 and p63 while 48 for MIB-1 and 16 for S100. The antibodies clones and dilutions were as follows: MIB-1 (Ventana rabbit monoclonal antibody clone 30-9, dilution 1: 200), p40 (Millipore rabbit polyclonal antibody PC373, dilution 1: 3000), p63 (Ventana prediluted mouse monoclonal antibody 4A4), and S100 (DAKO rabbit polyclonal antibody Z0311, dilution 1:8000). Disease-free survival (DFS) was calculated from the date of surgery to the date of first recurrence. The cutoff values of the amount of architectural patterns and mitotic index were calculated based on receiver operating characteristic curves and log rank test to determine the best threshold to predict DFS. The values that generated the most significant P-values were used in the subsequent analyses. Prognostic value of each clinicopathologic feature was determined using log rank test and DFS. Prognostic variables that were significant on univariate analyses were subsequently subjected to multivariate analyses using the Cox proportional hazards model. Interobserver agreement was assessed using k statistics. P-values <0.05 were considered to be statistically significant.
RESULTS
Clinicopathologic Characteristics of the Study Cohort
The clinicopathologic features of the primary tumors are summarized in Table 1 . The average age at diagnosis was 60 years (SE of mean = 2 y; range, 22 to 84 y). There was a female predominance with a female to male ratio of 2:1. The majority of tumors (n = 65, 94%) originated from the minor salivary glands of the oral cavity or sinonasal tract, whereas the remaining (n = 4, 6%) affected the major salivary gland (parotid gland). The most frequent site of origin was palate (n = 39, 57%) followed by base of tongue (BOT, n = 10, 14%). The average tumor size was 2.1 cm (SE of mean SEM = 0.2 cm). Thirty-three (n = 33, 48%) tumors were limited to lamina propria, whereas the remainder invaded skeletal muscle (n = 20, 29%) and/or bone (n = 16, 23%). Among the 18 patients who underwent neck dissection at the time of initial surgery, 10 (56%) harbored metastases to cervical lymph nodes.
Histologically, all tumors demonstrated invasive border, in the form of infiltrative islands (97%) or pushing nodules (3%). Chromatin clearing was variably present in all tumors, involving an average of 64% of cells per tumor. PNI was a common finding in our cohort, present in 41 (59%) tumors. The median number of PNI foci was 2 (range, 1 to 42). The number and percentage of cases demonstrating LVI, positive surgical margin, tumor necrosis, atypical mitosis, and apoptosis were as follows: 4 (6%), 16 (25%), 8 (12%), 4 (6%), and 34 (49%) ( Table 1 ). The average mitotic index of these tumors was 3 per 10 HPFs (range, 0 to 14/10 HPFs). Seventeen tumors (25%) demonstrated elevated mitotic rate of Z5/10 HPFs. Among the 48 tumors in which MIB-1 immunohistochemistry (IHC) were performed, 4 carcinomas (8%) exhibited elevated MIB-1 proliferation index of Z10%, whereas the remaining 44 had a low proliferation rate of <10%.
Tumor Subclassification and Associated Clinicohistologic Characteristics
After consensus review, 23 cases (33%) were classified as PLGA, 21 (30%) as CASG, 22 (32%) as TIF, and 3 (4%) as TPPP. k statistics showed a substantial interobserver agreement between the individual pathologists (k = 0.607; 95% confidence interval, 0.516 to 0.699) ( Table 2) . A substantial interobserver agreement was achieved for the individual diagnosis of PLGA, CASG, and TPPP (k = 0.677, 0.691, and 0.704, respectively), whereas the category of TIF generated significant interobserver discordance with only a fair to moderate agreement among pathologists (k = 0.402). The k values between the diagnoses of each individual pathologist and the consensus diagnoses ranged from 0.552 to 0.937 ( Table 2) .
There was no significant difference among different tumor types (PLGA, CASG, TIF, and TPPP) in terms of age at presentation, sex, tumor size, surgical margin status, involvement of cervical lymph nodes, tumor borders, presence of LVI, and atypical mitosis ( Table 1 , w 2 test or 1-way analysis of variance, P > 0.05). Compared with PLGA, CASG displayed higher rate of skeletal muscle and bone invasion (P = 0.045), higher mitotic index (P = 0.029), lower rate of PNI (P = 0.045), higher association with tumor necrosis (P = 0.007) and apoptosis (P = 0.042), and a significant higher association with BOT location (P = 0.014). CASG also showed higher percentage of tumor cells with chromatin clearing (70% ± 6%) in comparison with PLGA (56% ± 5%). However, the extent of chromatin clearing did not reach a significant level among the various tumor subtypes (PLAG, CASG, TIF, and TPPP) (P = 0.057).
CASGs were associated with a significantly higher percentage of papillary, solid, and cribriform patterns; whereas PLGAs contained a higher proportion of reticular, tubular, and single file patterns (P < 0.05) ( Table 1 ). In CASG, the most common architectural pattern was solid in 33%, cribriform in 24%, and papillary in 19% ( Fig. 3 ), whereas the architectural patterns in PLGAs were more evenly distributed across different recognizable patterns.
By IHC, there was no difference in staining pattern among different tumor types (PLGA, CA, SG, TIF, and TPPP, Table 1 ). S100 was universally positive in all 16 tumors tested, including 2 PLGA, 6 TIF, 7 CASG, and 1 TPPP. P63 and p40 immunohistochemical stains were performed on 46 randomly selected cases to verify a recent reported observation of positive p63 and negative p40 staining in PLGA. The majority of tumors were found to be negative for p40 (44, 96%) and positive for p63 (36, 78%). However, 10 cases (22%) were completely negative for p63 and 2 were focally positive for p40 (4%). The MIB-1 proliferation index did not differ significantly among different tumor types (P = 0.120). Factors associated with adverse clinical outcome (ie, DFS) included large tumor size (log rank test, P = 0.014), invasion into skeletal muscle and/or bone (P = 0.006), presence of LVI (P = 0.005), tumor necrosis (P = 0.018), Z10% of papillary architecture (P = 0.004), Z30% of cribriform pattern (P = 0.005), and Z50% of cribriform and solid patterns (P = 0.020, Table 3 ). The Kaplan Meier plots for DFS stratified by the above-mentioned factors are shown in Figure 4 .
Although CASG and TPPP appeared to associate with worse prognosis on Kaplan Maier plot compared with TIF and PLGA, log rank test failed to demonstrate a significant association between overall tumor classification and DFS (P = 0.103, Fig. 4A ).
Moreover, we compared the prognostic value of different percentage cutoff values of papillary, cribriform, and solid patterns. A cutoff of 10% or more papillary architecture seemed to correlate the best with DFS compared with 20% or 30% (10%: P = 0.004; 20%: P = 0.097, 30%: P = 0.045). A cutoff of 30% cribriform pattern was associated with DFS (P = 0.005), whereas 10% did not predict DFS (P = 0.881). The proportion of solid pattern at different percentages did not predict outcome (P > 0.05). Tumor with 10% or more papillary architectures were associated with a mitotic index of Z4/ 10 HPFs, a MIB-1 proliferation index of Z10%, and higher frequency of tumor necrosis (Fisher exact test, P < 0.001, <0.001, 0.001, and 0.022, respectively). The presence of Z30% cribriform architecture did not correlate with mitotic index, MIB-1 index, or tumor necrosis (P = 0.281).
On multivariate analysis using Cox proportional hazards model, the presence of Z10% papillary and Z30% cribriform patterns independently predicted DFS (Z10% papillary: hazard ratio = 24.7, 95% confidence interval = 1.1-570.1, P = 0.045; and Z30% cribriform: hazard ratio = 12.2, 95% confidence interval = 1.0-148.2, P = 0.049), whereas tumor size, bone invasion, tumor necrosis, and LVI failed to reach significance (P = 0.402, 0.119, 0.755, and 0.993, respectively). Six of 23 (26%) tumors with Z10% papillary features and 3 of 8 (38%) with Z30% cribriform pattern developed recurrence while only 1 of 37 (3%) tumor with <10%papillary pattern and 4 of 52 (8%) with <30% cribriform pattern recurred ( Table 3 ). The patient who died from her disease harbored a CASG showing >30% cribriform pattern.
DISCUSSION
In general, PLGA is considered as a low-grade epithelial malignancy with a low risk of local and regional recurrence but negligible risk for distant metastases. 1 The reported frequency of locoregional recurrence is up to 33%. 6 The rate of cervical lymph node metastases (at presentation or as a regional recurrence) ranges from 13% to 17%. 5, 6 In our cohort, the frequency of lymph node metastasis was 56% among 18 patients who had lymph node dissection and 14% overall. The high rate of lymph node metastasis among patients who underwent neck dissection might reflect selection bias as neck dissection was a selective surgical procedure for patients with suspicious neck lymph nodes.
Distant metastasis, although rare, has been reported in PLGA with an incidence of 0.6% 7 to 7.5%. 5 The reported sites of metastasis include lung, bone, skin, and subcutaneous tissue. 5, 7, 8 In the largest reported study on PLGA to date which was published in 1999 by the Armed Forces Institute of Pathology encompassing 164 cases, 1 patient (0.6%) developed distant metastasis to lung, 10.9 years after the initial resection and 3 patients (2%) died of their disease with an average survival of 71.5 months. The above data are in accordance with the overall rates of lymph node and distant metastasis found in the current series (17% and 3%, respectively). In the Armed Forces Institute of Pathology study, the disease-specific survival was reported as 98%. 7 In our study, 1 patient died of her disease, 9.3 years after the initial diagnosis. This is the seventh reported death in PLGA/CASG and the first to be related to distant metastasis. The other 6 documented deaths were reported by Castle et al 7 and Evans and Luna 5 and they were due to uncontrollable local recurrence.
Despite its general perception as low grade as its term implies, PLGA does not always behave as a lowgrade malignancy. Indeed, it is associated with a nonnegligible risk for regional disease, a small risk for distant metastasis, and even death of disease. As shown in this study, elective neck dissection and postoperative long-term surveillance are necessary in some instances. Therefore, in our opinion, the term "polymorphous adenocarcinoma" might be a better term to reflect the spectrum of tumor behavior than the term "polymorphous low-grade adenocarcinoma."
Although PLGA was described as an entity >40 years ago, 1 its prognostic factors are still not well delineated, and to date, only 3 published studies have utilized univariate survival analysis to investigate the potential prognostic factors in PLGA. 5, 6 The first reported study by Evans and Luna 5 failed to identified any significant clinical or pathologic predictor for overall survival in 40 patients with PLGA. In the second study, Seethala et al 6 have found that tumor site is the only significant determinant of DFS, whereas in the third national Danish study, Elhakim et al 15 have suggested that negative resection margins can improve DFS significantly. Despite of the relatively low statistical power and limited number of recurrences, in contrast to the prior studies, we were able to perform both univariate and multivariate analysis in a large cohort of patients with long-term clinical follow-up. On univariate analysis, tumor size, bone invasion, tumor necrosis, and LVI were significant prognostic elements. However, only 2 variables (Z10% papillary and Z30% cribriform growth pattern) were shown to independently predict shorter DFS by multivariate analysis. In view of these findings, it is important to recognize and document the presence and percentage of papillary and cribriform patterns in the surgical pathology report. However, it probably will take efforts to widely incorporate a relatively subjective histologic feature into the routine practice. Perhaps, similar to solid growth in adenoid cystic carcinoma, it is the presence and amount of papillary and cribriform patterns that drive outcome in the PLGA spectrum rather than the subtype of these tumors.
When the diagnosis of PLGA is histologically challenging, IHC can be helpful. A recent study by Rooper et al 16 has suggested the utility of a combined p63/p40 immunohistochemical stains in diagnosing PLGA. The authors have reported a consistent positive staining for p63 and negative staining for p40 in 11 PLGAs. This staining pattern has been observed to be distinctly different from the staining of adenoid cystic carcinoma which is typically positive for both p63 and p40. To verify this observation, we stained a larger number of PLGAs/CAMGs (n = 46) for p63 and p40. Similar to the prior study, we found that the majority of tumors were positive for p63 and negative for p40. However, 22% of tumors were completely negative for p63 and 4% were focally positive for p40. Such differences in immunophenotype might be in part related to the different antibodies utilized in these studies. Although Rooper and colleagues used monoclonal p63 and p40 antibodies (BioCare Medical), the p63 and p40 antibodies from the current study were polyclonal (Ventana Medical Systems Inc. and Millipore EMD Life Science). Nevertheless, our results suggest that PLGA/ CASG spectrum of tumors can exhibit a variable p63/ p40 immunostaining and that immunostaining results should be interpreted with caution and in the context of tumor morphology. Ongoing controversies exist regarding CASG and PLGA with significant papillary architecture or LGPA. The dispute centers on whether these 2 tumors represent discrete separate entities or variants of PLGA. 5, [8] [9] [10] The LGPA and CASG as entities distinct from PLGA to emphasize their more aggressive behaviors and higher risk of regional and distant metastases. [8] [9] [10] 13 As focal papillary, cribriform, or solid growth patterns have been described and accepted in an otherwise classical PLGA, 5, 7, 12, 14, 17 it can be challenging in some instances to separate these 3 tumors apart histologically. 14 LGPA was first described by Allen et al 18 in 1974 and subsequently by Mills et al in 1984. 11 Slootweg and Muller, 19 in 1987, have compared the clinical outcomes of 7 LGPA and 8 PLGA and have suggested that LGPAs are more frequently associated with regional metastasis. In 2000, Evans and Luna 5 have studied 40 cases of PLGA and have concluded that "more than focal" papillary area in an otherwise typical PLGA is associated with high risk of lymph node metastasis. Nevertheless, the precise amount of "more than focal papillary area" was not reported in their study. In addition, few prior studies have advocated using the term "LGPA" for tumors with histologic features of PLGA and papillary architecture, showing a higher rate of local recurrence (38% to 45%) and regional metastasis (25% to 35%) in these tumors compared with typical PLGA (23% and 10%, respectively). 8, 19 Although a study by Hunter and colleagues has proposed 10% as a cutoff for significant papillary architecture in PLGA, this was arbitrary proposed and was not supported by a statistical analysis. Thus, a precise threshold of significant papillary growth in PLGA has not been established to date. 8 In our hands, 10% or more papillary architecture seemed to be a significant independent predictor for DFS. We, therefore, recommend that the percentage of papillary architecture be documented in these tumors.
Cribriform adenocarcinoma was first described as cribriform adenocarcinoma of tongue in 1999 by Michal and colleagues. This tumor was felt to be discrete in that it usually arose in the BOT, had lymph node metastasis at time of presentation, and was characterized by predominant cribriform and solid growth patterns and optically clear nuclei. 20 In 2011, the same authors have subsequently published a larger series of 23 tumors, including tumors with same morphologic features in other minor salivary gland sites. Hence, the entity has been named as cribriform adenocarcinoma of minor salivary gland. 9 Thirty-one cases of cribriform adenocarcinoma have been published to date, all of which arose in the minor salivary gland of oral cavity and oropharynx. 10 Our results showed that this tumor is not limited to minor salivary gland and can occur in major salivary gland as well. Therefore, the term "cribriform adenocarcinoma of salivary glands (CASG)" might be a better term to describe this tumor.
Although several authors have argued that CASG is histologically distinct from PLGA, 9, 10, 20 a recent study has shown a significant proportion (about 35%) of the tumors on the PLGA spectrum exhibiting mixed morphology between PLGA and CASG. 14 Our study further supports such findings as we found that about a third of the cases harbor indeterminate morphology between PLGA and CASG. Although, a substantial interobserver concordance was identified among individual pathologists in our entire cohort of cases, TIFs imposed a diagnostic challenge with only fair to moderate interobserver agreement among expert pathologists. Taken together, although CASG displays a distinct morphology, it shows a morphologic overlap with PLGA, which may create difficulties in classifying this tumor.
Furthermore, recent studies have reported characteristic molecular alterations in PLGA/CASG spectrum of tumors. 14, 21, 22 Fusions involving Protein Kinase D1 (PRKD1), PRKD2, or PRKD3 loci have been detected in 80% of CASG, 45% of TIF, and 6% of PLGA. 14 PRKD1 hotspot somatic mutation encoding p.Glu710Asp is reported in 73% of PLGA. 21 The fact that PLGA and CASG have alterations affecting the same gene locus and that PRKD1/2/3 fusion can be seen in PLGA, TIF, and CASG suggest that these tumors might also have overlapping molecular signatures. Additional studies are needed to better classify these tumors, especially those with unusual or indeterminate features, at the molecular level.
When correlating tumor classification with clinicopathologic features and DFS, TPPP seemed to cluster with CASG. In comparison with PLGAs and TIFs, CASGs and TPPPs were more frequently seen in BOT, had a higher rate of bone invasion, a higher mitotic rate, and a higher percentage of tumor necrosis. However, CASG as defined in the literature does not seem to correlate with worse outcome. Interestingly, we have demonstrated that PLGA and TIF were associated with higher incidence of PNI (65% and 77%, respectively) compared with CASG and TPPP (38% and 33%, respectively), which may suggest that PLGA and TIF are more neurotropic. Despite the above correlation between TPPP and CASG as a group and aggressive clinicopathologic features, individual histologic entities do not seem to predict recurrence. Rather it is the amount of papillary and cribriform areas (Z10% papillary and Z30% cribriform growth pattern) that guides outcome in an independent manner. In view of these findings, the percentage of papillary and cribriform areas should be mentioned in the pathology report as these 2 features rather than tumor subtyping seem to drive the outcome in the spectrum of PLGA.
